Advertisement
Advertisement
U.S. Markets close in 5 hrs 25 mins
Advertisement
Advertisement
Advertisement
Advertisement

Sinovac Biotech Ltd. (SVA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.470.00 (0.00%)
As of 09:36AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.47
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's Range6.47 - 6.47
52 Week Range6.47 - 6.47
VolumeN/A
Avg. Volume0
Market Cap642.437M
Beta (5Y Monthly)N/A
PE Ratio (TTM)6.66
EPS (TTM)N/A
Earnings DateDec 06, 2021 - Dec 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • Business Wire

    SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

    BEIJING, September 06, 2022--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Pública, ISP) approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine (ancestral, Delta and Omicron variants) on August 31st. The clinical trial will evaluate the immunogenicity and safety of one booster dose of th

  • Business Wire

    SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

    BEIJING, August 03, 2022--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination for local children and adolescents, the Health Bureau of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China has approved the Company’s COVID-19 vaccine (CoronaVac), intended for children aged 6 months to 3 years.

  • Business Wire

    SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile

    BEIJING, July 19, 2022--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Católica de Chile (PI Dr. Pablo González). Study results will provide scientific evidence to support SINOVAC’s influenza vaccine immunogenicity and protection

Advertisement
Advertisement